Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the U.S. Food and Drug ...
FDA approves Guardant Health's blood test to help identify metastatic colorectal cancer patients eligible for targeted ...
The U.S. Food and Drug Administration (FDA) has approved Guardant360 CDx as a companion diagnostic to identify patients with ...
MedPage Today on MSN
Targeted duo wins again in BRAF-mutant colorectal cancer
Response rates with encorafenib-cetuximab plus FOLFIRI similar to combo plus modified FOLF ...
Amivantamab combined with FOLFOX or FOLFIRI showed a 51% overall response rate in RAS/BRAF wild-type mCRC patients, with a ...
Investigators assessed whether anticoagulation and platelet aggregation inhibition could have antitumoral effects when used along side targeted therapies for patients with unresectable stage III-IV ...
In BREAKWATER, EC plus FOLFIRI achieved a 64.4% response rate and showed a trend toward improved overall survival in patients ...
NEW YORK (Reuters) - Pfizer is trying to increase doctor awareness of and testing for a rare lung cancer mutation to help boost use of its drug Braftovi, which the pharmaceutical maker anticipates ...
In the evolving landscape of metastatic colorectal cancer, managing patients with RAS/BRAF wild-type tumors remains a ...
A new research perspective was published in Oncotarget's Volume 15 on July 16, 2024, entitled, "Targeting the multifaceted BRAF in cancer: New directions." In cancer patients, BRAF-targeting precision ...
BRAF-positive non-small cell lung cancer (NSCLC) treatments can use the BRAF biomarker to provide effective, targeted treatment for this subset of lung cancer. BRAF-positive NSCLC is an uncommon or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results